· AIM:To compare the clinical curative effect of triamcinolone acetonide and Ranibizumab on diffuse diabetic macular edema (DME).· METHODS:We collected 84 cases of patients with diffuse DME treated in our hospital from February 2016 to May 2017.According to 1:1 matching method,they were divided into Ⅰ,Ⅱ groups.They were all treated with laser photocoagulation.Preoperative auxiliary application of triamcinolone acetonide was given to Group Ⅰ,while Group Ⅱ received preoperative application of ranibizumab.After treatment,the efficacy of the two groups were analyzed and compared.· RESULTS:The total clinical efficiency of Group Ⅱ at 3mo after treatment was 93％,higher than that of Group Ⅰ (77％;x2 =4.981,P =0.025).Compared with before treatment,BCVA and CMT of the two groups at each time after treatment were significantly improved (P＜ 0.05).BCVA of Group Ⅱ at 1 and 3mo after treatment was better than that of Group Ⅰ (P＜0.05);CMT of Group Ⅱ at 1,3 and 6mo after treatment improved more than that of Group Ⅰ,with significant difference (P ＜ 0.05);occurrence rate of adverse reactions Group Ⅰ and Group Ⅱ were 17％ and 13％ with no significant statistical difference (X2 =0.243,P=0.621).There were no serious adverse reactions such as retinal detachment,endophthalmitis or cataract in the two groups.· CONCLUSION:Compared with triamcinolone acetonide,the effect of ranibizumab on diffuse diabetic macular edema is better,and has high clinical value.%目的:对曲安奈德与雷珠单抗用于弥漫性糖尿病性黄斑水肿(DME)的临床疗效观察比较.方法:将2016-02/2017-05我院收治的84例弥漫性DME患者作为研究对象,遵循1:1的配对原则将患者分为Ⅰ、Ⅱ两组,两组均采用激光光凝手术治疗,Ⅰ组光凝术前予以曲安奈德辅助治疗,Ⅱ组术前予以雷珠单抗辅助治疗,对两组临床疗效作回顾性分析与比较.结果:Ⅱ组患者治疗后3mo临床总有效率为93％,高于Ⅰ组总有效率77％ (x2=4.981,P=0.025);与治疗前相比,两组治疗后各时间段BCVA、CMT均得到明显改善(P＜0.05);Ⅱ组治疗后1、3mo BCVA指标改善优于Ⅰ组(P＜0.05);Ⅱ组治疗后1、3、6mo CMT改善更优于Ⅰ组,差异有统计学意义(P＜0.05);Ⅰ组与Ⅱ组不良反应发生率分别为17％、13％,差异无统计学意义(x2=0.243,P=0.621).两组均未发生视网膜脱落、眼内炎、白内障等严重的不良反应.结论:与曲安奈德相比较,雷珠单抗用于弥漫性DME的疗效更佳,具有较高的临床应用价值.
展开▼
